Efficacity and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients

Bullous pemphigoid (BP) is the most common auto immune blistering disease in Europe and its treatment can be challenging. Several published cases reported dupilumab efficiency in refractory patients. We conducted a retrospective multicentric study including 36 patients to evaluate real-life efficien...

Full description

Saved in:
Bibliographic Details
Published in:British journal of dermatology (1951) 2023-05
Main Authors: Moghadam, Parna, Tancrede, Emmanuelle, Bouaziz, Jean-David, Kallout, Julien, Bedane, Christophe, Begon, Edouard, Bourgault-Villada, Isabelle, Calugareanu, Andreea, Dereure, Olivier, Jendoubi, Fatma, Pham-Ledard, Anne, Ingen-Housz-Oro, Saskia, Picard-Dahan, Catherine, Viguier, Manuelle, Mahevas, Thibault, Jachiet, Marie, Charvet, Estelle, Cassius, Charles, Alexandre, Marina, Lepelletier, Clémence
Format: Article
Language:English
Subjects:
Dermatology
Human health and pathology
Life Sciences
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bullous pemphigoid (BP) is the most common auto immune blistering disease in Europe and its treatment can be challenging. Several published cases reported dupilumab efficiency in refractory patients. We conducted a retrospective multicentric study including 36 patients to evaluate real-life efficiency of dupilumab in BP. Our results suggest that dupilumab in association with high potency topical steroids could be rapidly effective in various clinical forms of BP and seems to be well tolerated in elderly population.
ISSN:0007-0963
1365-2133
DOI:10.1093/bjd/ljad136